首页> 外文期刊>European review for medical and pharmacological sciences. >An investigation of the concomitant use of angiotensin-converting enzyme inhibitors, non-steroidal anti-inflammatory drugs and diuretics
【24h】

An investigation of the concomitant use of angiotensin-converting enzyme inhibitors, non-steroidal anti-inflammatory drugs and diuretics

机译:血管紧张素转换酶抑制剂,非甾体类抗炎药和利尿剂同时使用的研究

获取原文
           

摘要

OBJECTIVE: To determine in retrospective data the prevalence at hospital discharge of co-prescribing angiotensin-converting enzyme inhibitors (ACE-I) and non-steroidal anti-inflammatory drugs (NSAIDs) and ACE-I/NSAIDs and diuretics and to identify factors associated with the co-prescription. Secondary, we evaluated the extent of serum creatinine and potassium monitoring in patients treated with ACE-I and these associations and determined the prevalence of values above the upper normal limit (UNL) in monitored patients. PATIENTS AND METHODS: Hospitalized patients with ACE-I in their therapy at discharge were included in 3 groups as follows: ACE-I, DT (double therapy with ACE-I and NSAIDs) and TT (triple therapy with ACE-I, NSAIDs and diuretics) groups. We evaluated differences on demographic characteristics, co-morbidities, medications, laboratory monitoring and quantified the patients with serum creatinine and potassium levels above the UNL using descriptive statistics. Logistic regression analysis with backward elimination was performed to identify significant predictors of combination therapy. RESULTS: Of 9960 admitted patients, 1214 were prescribed ACE-I, 40 were prescribed ACE-I/NSAIDs and 22 were prescribed ACE-I/NSAIDs/diuretics (3.13% and 1.72%, respectively, of the patients prescribed with ACE-I). Serum creatinine and potassium were monitored for the great majority of patients from all groups. The highest percentage of hyperkalemia was found in the DT group (10% of the patients) and of serum creatinine above UNL in the TT group (45.45%). The logistic regression final model showed that younger patients and monitoring for potassium were significantly associated with combination therapy. CONCLUSIONS: The prevalence of patients receiving DT/TT was relatively low and their monitoring during hospitalization was high. Factors associated with the combinations were younger patients and patients not tested for serum potassium.
机译:目的:确定回顾性数据,确定出院时同时使用血管紧张素转换酶抑制剂(ACE-I)和非甾体类抗炎药(NSAIDs),ACE-I / NSAIDs和利尿剂的发生率,并确定相关因素与共同处方。其次,我们评估了接受ACE-I治疗的患者的血清肌酐和钾监测程度以及这些关联,并确定了受监测患者中高于正常上限(UNL)的患病率。患者和方法:住院的出院时接受ACE-I治疗的患者分为3组:ACE-I,DT(使用ACE-1和NSAID的双重疗法)和TT(使用ACE-1,NSAID和AES的三联疗法)。利尿剂)组。我们评估了人口统计学特征,合并症,药物,实验室监测方面的差异,并使用描述性统计数据对血清肌酐和钾水平高于UNL的患者进行了量化。进行了向后消除的逻辑回归分析,以确定联合治疗的重要预测指标。结果:在9960名入院患者中,有1214例接受ACE-I处方,40例接受ACE-I / NSAIDs处方,22例接受ACE-I / NSAIDs /利尿剂处方(分别占ACE-I处方患者的3.13%和1.72% )。监测了所有组中绝大多数患者的血清肌酐和钾。在DT组(占患者的10%)中发现高钾血症的百分比最高,在TT组(45.45%)发现血清肌酐高于UNL。 Logistic回归最终模型显示,年轻患者和钾监测与联合治疗显着相关。结论:接受DT / TT治疗的患者患病率较低,住院期间的监测率较高。与这些组合相关的因素是年轻患者和未接受血清钾测试的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号